Regulatory Filings • Feb 19, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
PRESS RELEASE PRESS RELEASE PRESS RELEASE
Paris, February 19, 2015 – NEOVACS (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, announced today that the Company will be presenting at the BIO Europe Spring 2015 Partnering Conference to be held in Paris, Porte de Versailles, on March 9-11, 2015.
The spring edition of BIO Europe Conference attracts thousands of representatives from the biotechnology and pharmaceutical industries.
Miguel Sieler, CEO of Neovacs, will present on March 10, 2015 at 4:30 pm C.E.T. Neovacs will be attending the three-day conference with a booth.
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
Contacts
Nathalie Trépo +33 (0)1 53 10 93 00 [email protected]
Press – Financial Communications- Publicis Stéphanie Tabouis +33 (0) 1 44 82 46 35 sté[email protected]
Investor Relations – Financial Communications Germany – MC Services Raimund Gabriel +49-89-210228-30 [email protected]
Press – U.S. Inquiries – The Ruth Group Melanie Sollid-Penton 1.646.536.7023 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.